Maintenance Intermittent Therapy for Symptomatic GERD Patients
Completed · Phase 2 · Has a placebo group
Conditions studied: Gastroesophageal Reflux Disease
In brief
The purpose of this study to determine the efficacy of 20 mg of rabeprazole given as a maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal Reflux Disease (s-GERD).
Key facts
- Study ID
- NCT00165841
- Run by
- Eisai Inc.
- People needed
- 200
- Starts
- 2004-10-01
- Expected to finish
- 2008-06-01
- Last updated by the study team
- 2013-05-20
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Quality Care Medical Center Inc. — Vista, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.